Q2 result preview: Strong US performance to lift the show for pharma companies Pharma Q2 earnings: The strong US growth is to be led by new launches and stable generic pricing. The same will lift overall Q2 show even as domestic market may see moderate growth on high base and softness in acute segment.
Q2 result preview: Strong US performance to lift the show for pharma companies
- Konuyu başlatan Bilgin
- Başlangıç tarihi